Status:
COMPLETED
N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)
Lead Sponsor:
Quantinosis.ai LLC
Conditions:
Coronavirus
Covid19
Eligibility:
All Genders
18-90 years
Phase:
PHASE1
Brief Summary
This study examines the efficacy of N-acetylglucosamine (NAG) in treating patients with novel coronavirus (COVID-19) infection.
Detailed Description
This is a single center, prospective, observational cohort study. A total of 150 cases who test positive for the novel coronavirus (COVID-19) will be recruited. Presenting to the emergency room of the...
Eligibility Criteria
Inclusion
- ≥18 years old
- Treated with N-acetyl glucosamine (NAG) as first-line treatment
- Present with coronavirus disease 2019 (COVID-19) symptoms (including but not limited to fever, cough, shortness of breath, sore throat, nasal congestion, malaise, headache, muscle pain, loss of taste and/or smell, diarrhea, and vomiting)
- Clinically diagnosed with COVID-19 by reverse transcription polymerase chain reaction (RT-PCR)
- No intubation prior to hospitalization and enrollment in the current study.
Exclusion
- \<18 years old upon admission
- Allergy to NAG
- Allergy to shellfish
- Currently taking warfarin
- Currently pregnant or lactating
Key Trial Info
Start Date :
November 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 15 2021
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04706416
Start Date
November 14 2020
End Date
January 15 2021
Last Update
April 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Valley Baptist Medical Center
Harlingen, Texas, United States, 78550